Mestastop Solutions: Funding, Investors & Team (Oct 2026)

Problem Statement: Most current drugs approved for metastatic cancer, responsible for 90% of deaths, increase survival by a meagre few months. Clinicians need molecules that will delay the tumours' spread and empower them with more time to treat localized cancer. Additionally, the current method of stratifying patients at higher risk of metastasis via the node status often does not work, surprising clinicians. The Solution: Mestastop has identified the gaps as to why anti-metastasis drug discovery failed and has created three proprietary platforms integrating cell biology, genetic engineering, machine learning, animal pharmacology and clinical sampling that do the following: 1. Identifies the rate-limiting steps of metastasis, thereby discovering novel first-in-class targets 2. Screening platform to identify compounds that abrogate the rate-limiting steps 3. Screening platform that identifies the effect of approved drugs on the process of metastasis 4. Predicting the metastatic probability of a treatment-naive primary tumour patient with no second lesion

Mestastop Solutions has raised $540k across 1 round on record. The most recent is a Seed of $540k announced in Oct 2023.

Mestastop Solutions' most recent funding round on record is a Seed of $540k, announced in Oct 2023.

FundedIQ lists Arnab Roy Chowdhury (Founder) at Mestastop Solutions.

Mestastop Solutions is based in Bengaluru, Karnataka, India.

Mestastop Solutions is in the 11-50 employee band.

Mestastop Solutions' latest round of $540k is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.